Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OnconetixFRA:J4T 19 Receivables Turnover is 0.12 as of Mar. 2026. GuruFocus rates FRA:J4T with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 842 Biotechnology companies, Onconetix ranks better than 78.03% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Onconetix's Revenue for the
three
months ended in Mar. 2026 was €0.02 Mil. Onconetix's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.15 Mil.
Hence, Onconetix's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.12.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Onconetix Receivables Turnover Related Terms
Onconetix Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Onconetix's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J4T vs SPRC, ACUT, PPCB: Receivables Turnover Comparison
For the Biotechnology subindustry, Onconetix's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onconetix Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onconetix's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Onconetix's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onconetix (FRA:J4T) has a Receivables Turnover of 0.12 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Onconetix and its competitors. According to the industry distribution chart, Onconetix ranks #185 out of 842 companies in the Biotechnology industry, placing it in the top 22%.
Is Onconetix's Receivables Turnover too high?
Onconetix's current Receivables Turnover is 0.12. The Biotechnology industry median Receivables Turnover is 5.29. Onconetix's value of 0.12 is 97.7% below this industry median. Based on the distribution chart, Onconetix ranks #185 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Onconetix has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Receivables Turnover compare to SPRC and ACUT?
According to the Biotechnology industry distribution chart, Onconetix ranks #185 out of 842 companies for Receivables Turnover. This places Onconetix in the top 22% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Onconetix's value of 0.12 is 97.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onconetix's current Receivables Turnover of 0.12 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Onconetix and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onconetix's current Receivables Turnover is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (FRA:J4T) has a current Receivables Turnover of 0.12. The current Receivables Turnover is 0.12 and 97.7% below the Biotechnology industry median of 5.29. Onconetix's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Onconetix (FRA:J4T), the current Receivables Turnover is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
19GF Score
Get the complete analysis for FRA:J4T
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J4T has been successfully added to your 
